This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

6 Charts Explain An Ugly October for Biotech Stocks

IBB Chart IBB data by YCharts

October was the biotech sector's worst month in 2013.

"Worst" is relative in an otherwise unbelievable year for biotech stocks, but as you can see from the chart above, our little corner of the market was beat by the S&P 500 in October.

June was the only other month this year during which the S&P 500 outperformed the biotech sector, but the broader market just lost less. IBB Chart IBB data by YCharts

There are many reasons for the recent weakness in biotech stocks. As the year ends, some investors have definitely decided to lighten up on their winners.

Catalyst Pharmaceuticals (CPRX) was the best-performing stock between January and the end of September. And here's what Catalyst looked like in October: ^NBI Chart ^NBI data by YCharts

I probably had something to do with the Catalyst sell off.

Acadia Pharmaceuticals (ACAD - Get Report) was the second-best performing stock January through September. And in October: ACAD Chart ACAD data by YCharts

Celldex Therapeutics (CLDX - Get Report): Third-best return January through September. Not in October: nd CLDX Chart CLDX data by YCharts

Picking up the pattern? Here's Biocryst Pharmaceutics (BCRX - Get Report), fourth best until Octoer: ^NBI Chart ^NBI data by YCharts

-- Reported by Adam Feuerstein in Boston.

Follow Adam Feuerstein on Twitter.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ACAD $27.62 2.10%
BCRX $2.84 4.20%
CPRX $0.60 -1.40%
CLDX $3.50 0.29%
FB $119.49 1.40%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs